Skip to main content
ChemPartner PharmaTech Co., Ltd. logo

ChemPartner PharmaTech Co., Ltd. — Investor Relations & Filings

Ticker · 300149 ISIN · CNE100000Y27 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,256 across all filing types
Latest filing 2018-01-12 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300149

About ChemPartner PharmaTech Co., Ltd.

https://www.chempartner.com

ChemPartner PharmaTech Co., Ltd. is a global research and development organization providing comprehensive drug discovery and development services. Operating as a Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), the company supports pharmaceutical and biotechnology clients through an integrated service platform. Core capabilities include medicinal chemistry, biology, pharmacology, drug metabolism and pharmacokinetics (DMPK), and toxicology. The organization also offers specialized expertise in biologics discovery, protein engineering, and antibody development. ChemPartner facilitates the transition from early-stage research to clinical development through its pharmaceutical development and manufacturing capabilities, utilizing advanced technology to accelerate the discovery and production of novel therapeutic agents.

Recent filings

Filing Released Lang Actions
关于使用结余募集资金和超募资金及利息支付重大资产重组部分现金对价的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from a company regarding the use of surplus and over-raised funds and interest payments related to a significant asset restructuring involving partial cash consideration. It includes extensive information about the company's fundraising history, usage of funds, investment projects, financial data of the target company, risk analysis, and approvals from the board, independent directors, supervisory board, and sponsoring institutions. The document is not a full annual or interim financial report but rather a specific announcement about capital usage related to a major asset restructuring transaction. It does not contain comprehensive financial statements or quarterly results but focuses on capital/financing updates and related approvals. Therefore, the document fits best into the category of Capital/Financing Update (CAP).
2018-01-12 Chinese
发行股份及支付现金购买资产暨关联交易报告书
Capital/Financing Update Classification · 100% confidence The document is titled "发行股份及支付现金购买资产暨关联交易报告书," which translates to "Report on Issuance of Shares and Payment of Cash to Purchase Assets and Related Party Transactions." It is a detailed report concerning a major asset acquisition involving issuance of shares and cash payment, including related party transactions. The content includes detailed sections on transaction parties, asset valuation, issuance details, financial data, risk factors, legal opinions, and compliance analysis. This type of document is typical of a capital or financing update related to a significant corporate transaction rather than a general annual report or earnings release. It is not a brief announcement or a proxy statement, but a comprehensive report on a financing and asset acquisition transaction. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and detailed content confirm it is the report itself, not just an announcement or certification.
2018-01-12 Chinese
上海睿智化学研究有限公司截至2017年3月31日止3个月期间、2016年度及2015年度财务报表及审计报告
Audit Report / Information Classification · 100% confidence The document is a detailed financial report for Shanghai Ruizhi Chemical Research Co., Ltd. It includes audited financial statements for the three months ending March 31, 2017, and the full years 2016 and 2015. The content includes an audit report by PwC, consolidated and company balance sheets, income statements, cash flow statements, and notes to the financial statements. The presence of an audit report and comprehensive financial data for multiple periods indicates this is a standalone audit report document rather than a full annual report or interim report. The document length is substantial (15,000 characters), and it contains actual financial data and audit opinions, not just an announcement or certification. Therefore, the appropriate classification is Audit Report / Information (AR).
2018-01-12 Chinese
创业板上市公司重大资产重组方案首次披露对照表
M&A Activity Classification · 100% confidence The document is a detailed disclosure related to a major asset restructuring plan of a listed company, including extensive tables and checklists about the restructuring proposal, related approvals, financial reports, audit opinions, legal opinions, and other regulatory compliance documents. It references specific regulatory guidelines such as the "重组办法" (Restructuring Measures) and includes detailed financial and legal disclosures, independent financial advisor opinions, and risk disclosures. The document is comprehensive and contains substantive financial and legal information about the restructuring transaction, not merely an announcement or a brief summary. It is clearly a Major Asset Restructuring Report, which aligns with filings related to merger and acquisition activities. Given the detailed nature and the focus on restructuring, the most appropriate classification is "M&A Activity" (Code: TAR).
2018-01-12 Chinese
广发证券股份有限公司关于公司是否达到中国证监会《关于规范上市公司信息披露及相关各方行为的通知》第五条规定的股价波动情形之核查意见
Audit Report / Information Classification · 95% confidence The document is a report from an independent financial advisor (广发证券股份有限公司) regarding the stock price fluctuation of 量子高科（中国）生物股份有限公司 before a major asset restructuring transaction. It references compliance with the China Securities Regulatory Commission's notice on information disclosure and related behaviors, specifically about stock price volatility thresholds. The document contains detailed analysis of stock price movements over a specified period and concludes on whether abnormal fluctuations occurred. It is not an announcement of a report publication, nor a certification letter. It is a standalone audit or advisory report related to regulatory compliance and stock price behavior in connection with a major transaction. Therefore, it fits best under Audit Report / Information (AR). The document length is short but contains substantive analysis and conclusions, not just a brief announcement or certification.
2018-01-12 Chinese
简式权益变动报告书（一）
Major Shareholding Notification Classification · 95% confidence The document is titled as a "简式权益变动报告书" which translates to a "Simplified Equity Change Report". It details the change in shareholding of the company 量子高科（中国）生物股份有限公司, including information about shareholders, shareholding percentages before and after the transaction, the purpose of the equity change, agreements related to share issuance, and other related legal and financial details. The document references regulatory approvals from the China Securities Regulatory Commission (中国证监会) and Shenzhen Stock Exchange (深交所), and discusses share issuance and ownership changes exceeding 5%. This matches the definition of a Major Shareholding Notification (MRQ), which involves notification of changes in significant share ownership levels crossing thresholds. The document is not an announcement of a report publication, nor is it a full annual or interim report, audit report, or other categories. It is a detailed report on a significant shareholding change due to a transaction involving issuance of shares and cash payment for asset acquisition, consistent with MRQ filings.
2018-01-12 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.